Exclusion criteria were as follows: incomplete imaging data (n=47), incomplete clinicopathological records (n=29), HR-positive/HER2-negative subtype (n=407), bilateral breast cancer or concurrent primary malignancies at other sites (n=43), prior excision of the primary lesion before NAT (n=33), and post-NAT axillary intervention limited to sentinel lymph node biopsy or level I lymph node dissection (n=36). Here, ERBB2 is linked to breast carcinoma.